EUDA Health (EUDA) Stock Price, News & Analysis

Company Overview

EUDA Health, Inc. (NASDAQ:EUDA) is a healthcare technology company focused on the development and commercialization of digital health solutions and energy-based medical devices for women’s intimate health. The company’s platform combines non-invasive treatment devices with software-driven patient monitoring and analytics to support pelvic floor function, address stress urinary incontinence and enhance vaginal tissue health.

EUDA Health’s core product offerings utilize low-intensity radiofrequency energy delivered through proprietary handpieces to promote tissue remodeling and muscle activation. These in-office treatment systems are complemented by a secure digital health platform that enables telehealth consultations, remote patient monitoring and real-time data insights for clinicians, aiming to improve patient adherence and clinical outcomes.

The company distributes its devices and digital health services through a hybrid model of direct sales to healthcare practices and partnerships with established medical distributors. While its primary market is in the United States, EUDA Health has initiated market entry programs in select international regions and collaborates with clinical investigators to expand its evidence base.

Led by a management team with deep experience in medical device innovation, digital therapeutics and women’s health, EUDA Health continues to pursue regulatory clearances, strategic collaborations and product enhancements. Through ongoing research and development efforts, the company aims to broaden its therapeutic offerings and further integrate its digital platform capabilities within the continuum of care.

Key Stats

• Today's Range: $1.05 to $1.14
• 50-Day Range: $1.06 to $3.35
• 52-Week Range: $1.03 to $6.30
• Volume: 86,687 shs
• Average Volume: 154,719 shs
• Market Capitalization: $40.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

EUDA Health Stock Analysis - MarketRank™

EUDA Health scored higher than 9% of companies evaluated by MarketBeat, and ranked 933rd out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for EUDA Health.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for EUDA Health are expected to grow in the coming year, from ($0.33) to ($0.09) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.34% of the float of EUDA Health has been sold short.

Short Interest Ratio / Days to Cover

EUDA Health has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in EUDA Health has recently increased by 128.83%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

EUDA Health does not currently pay a dividend.

Dividend Growth

EUDA Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.34% of the float of EUDA Health has been sold short.

Short Interest Ratio / Days to Cover

EUDA Health has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in EUDA Health has recently increased by 128.83%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.36

News Sentiment

EUDA Health has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for EUDA Health this week, compared to 1 article on an average week.

MarketBeat Follows

8 people have added EUDA Health to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, EUDA Health insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 4.35% of the stock of EUDA Health is held by institutions.

EUDA Stock Analysis - Frequently Asked Questions

How have EUDA shares performed this year?

EUDA Health's stock was trading at $4.47 at the beginning of 2025. Since then, EUDA stock has decreased by 75.4% and is now trading at $1.10.

Who are EUDA Health's major shareholders?

Top institutional shareholders of EUDA Health include Hudson Bay Capital Management LP (2.14%) and Hudson Bay Capital Management LP (2.14%).

How do I buy shares of EUDA Health?

Shares of EUDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of EUDA Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that EUDA Health investors own include Aptorum Group (APM), Avalo Therapeutics (AVTX), Coya Therapeutics (COYA), Deswell Industries (DSWL), Dawson Geophysical (DWSN), GT Biopharma (GTBP) and iClick Interactive Asia Group (ICLK).

Company Calendar

• Today: 9/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:EUDA
• CIK: 1847846
• Web: euda.com
• Phone: 65-6788-0388
• Fax: 65-6788-0068
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.18
• Quick Ratio: 0.15

Sales & Book Value

• Annual Sales: $4.01 million
• Price / Sales: 10.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.07) per share
• Price / Book: -15.69

Miscellaneous

• Outstanding Shares: 37,160,000
• Free Float: N/A
• Market Cap: $40.80 million
• Optionable: Not Optionable
• Beta: -0.10